The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen announced it hosted Pennsylvania State Representatives Borowski and Friel at its facility this week, engaging directly with CEO Dr. Shankar Musunuri and the company team.
During the meeting, Ocugen shared updates on its current pipeline, ongoing projects, and discussed the potential implications of HB 2162, a legislative bill relevant to the company and the regional biotech sector. The discussions also covered perspectives on advancing innovation in biotechnology and the life sciences sector in Pennsylvania.
View post on X Loading...
Earlier this year, Ocugen began evaluating RORα as a multi-pathway target for Alzheimer’s research, focusing on neuroinflammation and mitochondrial health, according to company statements. The firm also strengthened its clinical development leadership with the appointment of Beth Scott to oversee advanced retinal therapy trials, per a prior announcement. These initiatives are part of Ocugen’s broader strategy in the biotechnology sector.